Skip to main content
Andrew L. Laccetti on Muck Rack

Andrew L. Laccetti

As seen in: European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew L.

Contact Andrew L., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial

|
By Kelly Fitzgerald, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Chung-Han Lee, Laura Peralta, Yingbei Chen, Robert A. Lefkowitz, Neil Shah Verified, Colette N. Owens, Deaglan J. McHugh, David H Aggen, Ritesh R. Kotecha, Andrew L. Laccetti, Darren R. Feld
| European Urology Verified
Abstract Treatment options are limited for patients with non–clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib plus nivolumab. We now report updated efficacy and safety results at median follow-up of 34 mo for patients with papillary, unclassified, or translocation-associated RCC.
Open in Who Shared Issue with article?
See all 1 articles